Navigation Links
DiagnoCure announces fourth quarter and full year 2008 earnings conference call and webcast
Date:12/5/2008

QUEBEC CITY, Dec. 5 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that the Company will release its fourth quarter and fiscal 2008 year end results on December 17, 2008, at approximately 5:00 p.m. (ET). This release will be followed by a conference call, which will be held on December 18, 2008, at 10:30 a.m. (ET). The conference will begin with a brief presentation, followed by a question-and-answer period.

The event will be webcast live through DiagnoCure's website at www.diagnocure.com, through a link on the Investors page - Presentations and Conferences.

For those who wish to take part in the conference call for the Q&A period, please dial (514) 807-8791 (Montreal area), (416) 644-3416 (Toronto area) or the toll-free number (800) 732-9307.

For those unable to participate, a replay of the audio conference will also be available on DiagnoCure's website as of December 19, 2008, also through a link on the Investors page - Presentations and Conferences.

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc., recently launched the Previstage(TM) GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. The Company also has a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure's proprietary molecular marker. This test is also available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in vitro assay, and in Canada. In addition to its own research, the Company intends to acquire or in-license additional promising cancer biomarkers from both academic and commercial institutions. For more information, visit www.diagnocure.com.

Forward-looking statements

This release contains forward-looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward-looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein.


'/>"/>
SOURCE DIAGNOCURE INC.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DiagnoCure to webcast presentation at the Piper Jaffray Health Care Conference on December 3, 2008
2. DiagnoCure to present at the JMP Securities Healthcare Focus Conference on October 6, 2008
3. Diagnocure announces sponsorship of inaugural undy 5,000 run - Partnership with the Colon Cancer Alliance creates patient awareness of previstage(TM) GCC staging test
4. DiagnoCures GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Group
5. DiagnoCure announces second quarter 2008 results
6. DiagnoCure to host Q2 2008 earnings conference call and webcast
7. DiagnoCures molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings
8. Susan G. Komen for the Cure(R) Announces Recipients of 2008 Komen Brinker Award for Scientific Distinction
9. Universal Health Realty Income Trust Announces Marc D. Miller Appointed to Board of Trustees and Dividend Increase
10. OneMedPlace announces panels for "OneMedForum 2009: Disrupters and Drivers in Eight Areas of Medical Technology" -- CEOs and investors to meet in unique format of focused sessions
11. Integrated Healthcare Holdings, Inc. Announces New Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 06, 2016 , ... GrekTek LLC, ( http://www.grektek.com ) an ... http://kck.st/2g3a1so ) for the HealthyWatch, a new device to help patients manage their ... watch while sharing these events with caregivers in real time. , ...
(Date:12/6/2016)... ... December 06, 2016 , ... Keeping Gift Season Safe, In a season stacked ... and age-appropriate for their recipients. This is the idea behind Safe Toys and Gifts ... items that would make good gifts for children. For companies that produce goods that ...
(Date:12/6/2016)... Overland Park, KS (PRWEB) , ... December 06, 2016 , ... ... online retailers of Mobility Scooters . , Mobility Scooters give freedom to people ... and balance problems. Still others may be facing a long period of rehabilitation after ...
(Date:12/6/2016)... ... December 06, 2016 , ... U.S. Security Associates (USA) was ... for their industry leading training methods that engage their associates and link their ... global elite in employer-sponsored training and development programs. , “The 2017 Training Top ...
(Date:12/5/2016)... ... December 05, 2016 , ... Edward ... to announce the arrival of the newest Sciton laser in January 2017. The ... use tunable non-ablative and ablative wavelengths for exceptional results. Outperforming more traditional lasers, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... YORK , Dec. 5, 2016  Balloon catheter ... catheter, which is inserted into the femoral artery in ... the arm to treat constricted blood vessels. These products ... due to atherosclerosis – deposition of lipid substances in ... balloon catheter market is projected to expand at a ...
(Date:12/5/2016)... Spain Glaucoma Surgery Devices Market Outlook to ... Surgery Devices Market Outlook to 2022", provides key market ... report provides value, in millions of US dollars, volume ... - Canaloplasty Micro Catheters and Glaucoma Drainage Devices. ... data for each of these market segements, and global ...
(Date:12/5/2016)... Dec. 5, 2016  Cornerstone Pharmaceuticals, Inc., a ... data from two Phase I trials evaluating its ... 58th annual meeting of the American Society of ... . The two datasets show encouraging efficacy ... leukemia (AML) and T-cell non-Hodgkin,s lymphoma (T-cell NHL), ...
Breaking Medicine Technology: